机构：[1]Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China[2]Department of Immunology, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China[3]Department of Neurosurgery, Xi’an No.3 Hospital, the Affiliated Hospital of Northwest University, Xi’an, Shaanxi 710018, China[4]Department of Thoracic and Cardiovascular Surgery, Dazhou Second People’s Hospital, Integrated TCM & Western Medicine Hospital, Dazhou 635000, China[5]Department of Pathology, Dazhou Second People’s Hospital, Integrated TCM & Western Medicine Hospital, Dazhou 635000, China[6]Department of Oncology & Cancer Institute, Sichuan Provincial People’s Hospital, Sichuan Academy of Medical Sciences, University of Electronic Science and Technology of China, Chengdu 610072, China四川省人民医院[7]Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China四川省人民医院
BackgroundPositive regulators of T-cell function (PTFRs), integral to T-cell proliferation and activation, have been identified as potential prognostic markers in colorectal cancer (CRC). Despite this, their role within the tumor microenvironment (TME) and their response to immunotherapy are not yet fully understood.MethodsThis study delved into PTFR-related CRC subtypes by analyzing four independent transcriptome datasets, emphasizing the most significant prognostic PTFRs. We identified differentially expressed genes (DEGs) between two subtypes and developed a PTFR risk model using LASSO and Cox regression methods. The model's associations with survival time, clinical features, TME characteristics, tumor mutation profiles, microsatellite instability (MSI), cancer stem cell (CSC) index, and responses to chemotherapy, targeted therapy, and immunotherapy were subsequently explored.ResultsThe PTFR risk model demonstrated a strong predictive capacity for CRC. It facilitated the estimation of immune cell composition, HLA expression levels, immune checkpoint expression, mutation burden, CSC index features, and the effectiveness of immunotherapy.ConclusionsThis study enhances our understanding of the role of PTFRs in CRC progression and introduces an innovative assessment framework for CRC immunotherapy. This framework improves the prediction of treatment outcomes and aids in the customization of therapeutic strategies.
基金：
National Natural Science Foundation of China,NO. 81873048 to CX; Medico-Engineering Cooperation Funds from University of Electronic Science and Technology of China, No. ZYGX2021YGCX004 to CX;The Intramural Fund of North Sichuan Medical College (CBY21-QD31) and Nanchong City Talent Development Fund (CBY23-NCR06) to KP.
第一作者机构：[1]Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, China
共同第一作者：
通讯作者：
通讯机构：[6]Department of Oncology & Cancer Institute, Sichuan Provincial People’s Hospital, Sichuan Academy of Medical Sciences, University of Electronic Science and Technology of China, Chengdu 610072, China[7]Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu 610072, China
推荐引用方式(GB/T 7714)：
Pu Ke,Gao Jingyuan,Feng Yang,et al.Comprehensive evaluation of immunological attributes and immunotherapy responses of positive T cell function regulators in colorectal cancer[J].BMC GASTROENTEROLOGY.2024,24(1):doi:10.1186/s12876-024-03409-2.
APA：
Pu, Ke,Gao, Jingyuan,Feng, Yang,Hu, Jian,Tang, Shunli...&Xu, Chuan.(2024).Comprehensive evaluation of immunological attributes and immunotherapy responses of positive T cell function regulators in colorectal cancer.BMC GASTROENTEROLOGY,24,(1)
MLA：
Pu, Ke,et al."Comprehensive evaluation of immunological attributes and immunotherapy responses of positive T cell function regulators in colorectal cancer".BMC GASTROENTEROLOGY 24..1(2024)
